Acrivon Therapeutics, Inc.
ACRV · XNASCIK 1781174fmd_13P7S5H4SVRTEFPYKMZEMAFA98Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | – | 24 | 46 | 64 | 60 |
| Total operating expenses | 16 | 33 | 67 | 89 | 84 |
| Operating income | (16) | (33) | (67) | (89) | (84) |
| Interest and investment income | – | 2 | 7 | – | – |
| Other non-operating income (expense) | (0) | 1 | 7 | 9 | 6 |
| Income before taxes | – | – | – | (80) | (78) |
| Income tax expense | – | – | – | – | 0 |
| Net income from continuing operations | – | – | – | – | (78) |
| Net income | (16) | (31) | (60) | (81) | (78) |